CARA — Cara Therapeutics Share Price
0.000.00%
Last trade - 00:00- $41.76m
- -$59.00m
- $20.97m
- 20
- 45
- 15
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 0.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.99 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -121.19% | ||
| Return on Equity | -109.8% | ||
| Operating Margin | -579.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 19.89 | 135.08 | 23.03 | 41.87 | 20.97 | 5.59 | 3.67 | 9.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Directors
- Christopher Posner PRE (52)
- Thomas Reilly CFO (49)
- Frederique Menzaghi SVP (54)
- Scott Terrillion CCO (58)
- Joana Goncalves OTH (47)
- Martin Vogelbaum LED (58)
- Harrison Bains IND (77)
- Jeffrey Ives IND (70)
- Susan Shiff IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 2nd, 2004
- Public Since
- January 31st, 2014
- No. of Shareholders
- 34
- No. of Employees
- 55
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 54,656,413
- Address
- 400 Atlantic Street, Suite 500, STAMFORD, 06901
- Web
- https://www.caratherapeutics.com/
- Phone
- +1 2034063700
- Auditors
- Ernst & Young LLP
Upcoming Events for CARA
Cara Therapeutics Inc Annual Shareholders Meeting
Cara Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Cara Therapeutics Inc Earnings Release
Similar to CARA
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Cara Therapeutics share price?
As of Today at 19:04 UTC, shares in Cara Therapeutics are trading at $0.76. This share price information is delayed by 15 minutes.
How has the Cara Therapeutics share price performed this year?
Shares in Cara Therapeutics last closed at $0.76 and the price had moved by -83.28% over the past 365 days. In terms of relative price strength the Cara Therapeutics share price has underperformed the S&P500 Index by -86.5% over the past year.
What are the analyst and broker recommendations for Cara Therapeutics?
The overall consensus recommendation for Cara Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cara Therapeutics dividend yield?
Cara Therapeutics does not currently pay a dividend.
Does Cara Therapeutics pay a dividend?
Cara Therapeutics does not currently pay a dividend.
When does Cara Therapeutics next pay dividends?
Cara Therapeutics does not currently pay a dividend.
How do I buy Cara Therapeutics shares?
To buy shares in Cara Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cara Therapeutics?
As of the previous close price of $0.76, shares in Cara Therapeutics had a market capitalisation of $41.76m.
Where are Cara Therapeutics shares listed?
Here are the trading details for Cara Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CARA
What kind of share is Cara Therapeutics?
Based on an overall assessment of its quality, value and momentum Cara Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cara Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Cara Therapeutics is $5.23. That is 584.47% above the last closing price of $0.76.
Analysts covering Cara Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.15 for the next financial year.
What is the trend in the Cara Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cara Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -54.06%.
As of the last closing price of $0.76, shares in Cara Therapeutics were trading -48.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cara Therapeutics PE Ratio?
The Cara Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cara Therapeutics?
Cara Therapeutics' management team is headed by:
- Christopher Posner - PRE
- Thomas Reilly - CFO
- Frederique Menzaghi - SVP
- Scott Terrillion - CCO
- Joana Goncalves - OTH
- Martin Vogelbaum - LED
- Harrison Bains - IND
- Jeffrey Ives - IND
- Susan Shiff - IND